Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing
Being part of a community will help keep you focused on goals Food is the last thing we're thinking of when we're not hungry
94% reduction in progression from pre diabetes to type 2 diabetes with tirzepatide.** **Based on a three-year clinical trial study (176-week treatment period) sponsored by Eli Lilly and Company, weekly injections of tirzepatide significantly reduced the risk of progression to type 2 diabetes by 94% in adults with prediabetes who were overweight or obese compared to placebo
Add to cart
It necessitated Mojsov injecting her lab-made peptides into rabbits once a week for three consecutive weeks to encourage their immune systems to produce specific antibodies against them which took about two months to happen (Mojsov, Heinrich, Wilson)
if confirmed, the medication should not be restarted) [1] You develop right-upper abdominal pain, jaundice (yellowing of skin/eyes), pale stools or dark urine (possible gallbladder disease) You develop chest pain, severe breathlessness, or signs of allergic reaction Joint pain follows trauma or injury with suspected fracture Your healthcare provider may undertake investigations including blood tests (inflammatory markers, rheumatoid factor, uric acid), X-rays, or referral to rheumatology if inflammatory arthritis is suspected
